All the gene capture panels used in our study, including 8, 56, 108, 168, and 295 cancer-related genes, interrogated whole exons and critical introns for the 8 classic NSCLC oncogenic drivers, which includes EGFR, ALK, BRAF, ERBB2, KRAS, MET, RET, and ROS1. To understand the impact of concomitant mutations, including TP53, other tumor suppressor genes, and oncogenic driver genes, on crizotinib outcomes, we selected the patient samples that were assayed using 168-gene or 295-gene panels (n = 94). This evidence concerns the gene MET and non-small cell lung carcinoma.